A ranar 19 ga Yuni, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta sanar da cewa an gabatar da shawarar IBI343 ta Innovent Biologics don shiga cikin shirin tantance maganin gaggawa, wanda aka yi niyya don maganin cutar kansar pancreas da ta bulla a cikin gida ko kuma ta kamu da cutar CLDN18.2 kuma ta sami akalla magunguna biyu a baya.
IBI343 wani maganin hana garkuwar jiki ne da aka sake haɗa shi da ɗan adam wanda aka haɗa shi da maganin rigakafi na CLDN18.2 (ADC). Bayan ya haɗu da ƙwayoyin ciwon da ke bayyana CLDN18.2, yana shiga cikin CLDN18.2-dogara da ADC kuma yana sakin wani abu mai guba na cytotoxic, wanda ke haifar da lalacewar DNA kuma a ƙarshe yana haifar da apoptosis na ƙwayoyin ciwon daji.
A ranar 9 ga Disamba, 2024, an gabatar da sabbin bayanai daga gwajin asibiti na Phase I (NCT05458219) na IBI343 a cikin adenocarcinoma na pancreas mai ci gaba (PDAC) a taron shekara-shekara na Ƙungiyar Kula da Cututtukan Lafiya ta Turai ta Asiya (ESMO Asia).
An yi wa jimillar marasa lafiya 43 da ke dauke da CLDN18.2-positive PDAC magani da IBI343. Sakamakon ya nuna jimlar adadin amsawar da aka yi da gangan (ORR) na kashi 32.6%, adadin amsawar da aka yi da gangan (cORR) na kashi 23.3%, da kuma adadin maganin cututtuka da aka tabbatar (cDCR) na kashi 81.4%. Matsakaicin tsawon lokacin amsawar (mDoR) shine watanni 7.0, tare da adadin DoR na watanni 6 na kashi 63%, kuma matsakaicin rayuwa ba tare da ci gaba ba (PFS) shine watanni 5.3.
A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.
Lambar Waya: 4008803716
Email：myimmnet@163.com
Lokacin Saƙo: Yuni-19-2025